Bruker completed the acquisition of PhenomeX for $108m.

Bruker, a manufacturer of scientific instruments, completed the acquisition of PhenomeX, a cell biology company, for $108m. “We are excited to welcome PhenomeX to Bruker. PhenomeX’s differentiated research tools are highly valued by customers in the attractive growth markets of antibody development, cell line development, cell and gene therapy, and many more. Also, PhenomeX’s platforms are highly complementary to our existing cellular and sub-cellular analysis tools including our high-performance CellScape™ spatial biology platform,” Mark R. Munch, Bruker President.